Role of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease

World Journal of Gastroenterology

Volumn 12, Issue 22, 2006, Pages 3461-3465

  Grier, Scott ^a   Lim, Adrian K P ^a   Patel, Nayna ^a   Cobbold, Jeremy F L ^a   Thomas, Howard C ^a   Cox, Isobel J ^a   Taylor Robinson, Simon D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatitis C; Microbubble contrast agents; Ultrasound

Indexed keywords

ALBUMIN; CYANOACRYLATE; ECHO CONTRAST MEDIUM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PERFLUTREN; PHOSPHOLIPID; SHU 508; SONOVUE; SURFACTANT;

CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE MARKER; DISEASE SEVERITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SPECIFICITY; ECHOGRAPHY; EDITORIAL; ERADICATION THERAPY; FUNCTIONAL ASSESSMENT; GOLD STANDARD; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER BLOOD VESSEL; MICROBUBBLE; MICROVASCULATURE; NON INVASIVE PROCEDURE; OPTICAL RESOLUTION; QUANTITATIVE ASSAY; SEROLOGY; UNSPECIFIED SIDE EFFECT;

EID: 33745726666     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i22.3461     Document Type: Editorial

References (25)

1. World Health Organisation. Hepatitis C factsheet no. 164, revised October 2000. Available from: URL: http//www.who.int/mediacentre/ factsheets/fsl64/en/
2. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891
3. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-S29
4. National Institute of Clinical Excellence (N.I.C.E.). Guidance on the use of ribavirin and interferon alpha for hepatitis C. October 2000. Available from: URL: http//www.nice.org.uk/pdf/RIBAVIRIN-guidancel4.pdf
5. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-S56
6. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Thabut D, Ratziu V, Benhamou Y. Biomarkers as non-invasive assessment of hepatic fibrosis in chronic hepatitis C. J Gastroenterol Hepatol 2004; 19: S236-S245
7. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-S64
8. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-1174
9. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-224
10. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075
11. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526
12. Kono Y, Mattrey RF. Ultrasound of the liver. Radiol Clin North Am 2005; 43: 815-826, vii
13. Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med 2002; 21: 1023-1032; quiz 1033-1034
14. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Ledinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54
15. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350
16. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-845
17. Blomley M, Cosgrove D. Microbubble echo-enhancers; a new direction for ultrasound? Lancet 1997; 349: 1855-1856
18. Becher H, Burns PN. Handbook of contrast echocardiography. LV function and myocardial perfusion (Electronic Version). Springer, 2000: 2-42. Available from: URL: http//www.sunnybrook.utoronto.ca/EchoHandbook/
19. Harvey CJ, Pilcher JM, Eckersley RJ, Blomley MJ, Cosgrove DO. Advances in ultrasound. Clin Radiol 2002; 57: 157-177
20. Harvey CJ, Blomley MJ, Eckersley RJ, Cosgrove DO. Developments in ultrasound contrast media. Eur Radiol 2001; 11: 675-689
21. Blomley MJ, Cooke JC, Unger EC, Monaghan MJ, Cosgrove DO. Microbubble contrast agents: a new era in ultrasound. BMJ 2001; 322: 222-1225
22. Blomley MJ, Lim AK, Harvey CJ, Patel N, Eckersley RJ, Basilico R, Heckemann R, Urbank A, Cosgrove DO, Taylor-Robinson SD. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study. Gut 2003; 52: 1188-1193
23. Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC, Cosgrove DO, Blomley MJ. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133
24. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank A, Butler-Barnes J, Patel N. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583
25. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699